🔗 Share this article

The recently developed medications for gonorrhoea in decades are being hailed as a "major milestone" in the effort against increasingly resistant strains of the pathogen, according to health experts.

A Worldwide Challenge

Cases of gonorrhoea are increasing globally, with data suggesting over 82 million instances per year. Especially elevated rates are reported in the African continent and nations within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune step in the context of growing infection rates, increasing antimicrobial resistance and the very limited treatment choices presently on offer.”

Public health authorities are increasingly worried about the surge in drug-resistant strains. The WHO has designated it as a "critical concern". A tracking program showed that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Secure Clearance

One new antibiotic, also known as a brand name, was approved by the American regulatory agency in December for use against gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Experts anticipate that specific application of this new drug will help slow the spread of drug resistance.

Gepotidacin, developed by the drugmaker GSK, gained clearance in concurrent days. This treatment, which is also used to treat urinary tract infections, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin stemmed from a unique collaborative effort for medication research. The non-profit organisation GARDP worked alongside the pharmaceutical company Innoviva to see it through.

“This approval signifies a major breakthrough in the treatment of highly resistant gonorrhoea, which until now has been outpacing medical innovation.”

Research Study Outcomes and Worldwide Availability

As per findings released by a prominent scientific publication, zoliflodacin cured over nine in ten of genital gonorrhoea infections. This puts it on an comparable level with the typical regimen, which combines a dual-drug approach. The trial included over 900 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, GARDP has the rights to license and sell the drug in numerous regions with limited resources.

Clinicians on the front lines have voiced hope. Having a single-dose, oral treatment of this kind is seen as a "revolutionary step" for gonorrhoea control. This is viewed as essential to lessen the impact of the illness for people and to prevent the spread of extremely resistant gonorrhoea worldwide.